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The current concept of basal ganglia organization and function in physiological and
pathophysiological conditions excludes the most numerous cells in the brain, i.e., the
astrocytes, present with a ratio of 10:1 neuron. Their role in neurodegenerative condition
such as Parkinson’s disease (PD) remains to be elucidated. Before embarking into
physiological investigations of the yet-to-be-identified “tripartite” synapses in the basal
ganglia in general and the striatum in particular, we therefore characterized anatomically
the PD-related modifications in astrocytic morphology, the changes in astrocytic network
connections and the consequences on the spatial relationship between astrocytic
processes and asymmetric synapses in normal and PD-like conditions in experimental and
human PD. Our results unravel a dramatic regulation of striatal astrocytosis supporting the
hypothesis of a key role in (dys) regulating corticostriatal transmission. Astrocytes and their
various properties might thus represent a therapeutic target in PD.
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INTRODUCTION
Dopamine (DA) deprivation in Parkinson’s disease (PD; Ehringer
and Hornykiewicz, 1960) provokes complex and multiple changes
in striatal DA target neurons that contribute to development of
characteristic motor disorders such as bradykinesia, rigidity and
resting tremor (Calabresi et al., 2000; Nicola et al., 2000). The
mechanisms triggering and/or contributing to the morphological
and functional modifications affecting the basal ganglia (BG)
network remain elusive (Gerfen and Surmeier, 2011; Picconi
et al., 2012). Puzzlingly enough, the role of astrocytes in such
complex pathological changes has almost remained untouched.
The current concept of BG organization and function excludes the
most numerous cells in the brain (Tsacopoulos and Magistretti,
1996). For decades, astrocytes have been regarded as passive
partners of neurons in the central nervous system, but this view
has been challenged and they are now integrated in the concept
of “tripartite synapse”. Indeed astrocytes have a multitude of
processes that are intertwined within the neuropil ensheathing
synaptic contacts, they possess receptors and reuptake sites for
neurotransmitters, so they sense and integrate synaptic activ-
ity. They are essential for the metabolic support of neurons
by promoting neurovascular coupling and for neurotransmitters
synthesis. Moreover, depending on intracellular Ca2+ levels, they
may release signaling molecules known as gliotransmitters that
have feedback actions on neurons (Perea et al., 2009; Parpura
et al., 2012; Santello et al., 2012). Astrocytes overlap little with
each other, forming a tiling organization that ensures that a given
set of synapses is covered by only one astroglial cell. One unique
feature of astrocytes is their high level of intercellular connec-
tivity mediated by connexins (Cx), the proteins forming gap
junction (GJ) channels, of which the Cx 43 and 30 are the main
species in the adult brain (Dermietzel et al., 1991; Nagy et al.,
1999). Cx are embedded in the plasma membrane and, when
associated head-to-head between two neighboring cells, form
a GJ. Cx can also operate as hemichannels, allowing exchange
of molecules between the cytoplasmic and extracellular media
(Hofer and Dermietzel, 1998). The central pore of hemichannels
or GJs allows the passage of ions and small molecules allowing
an ionic, biochemical or metabolic coupling with neighboring
cells.
It is likely that if so many important brain functions depend on
appropriate astrocyte-neuron interactions, some pathological sit-
uations might be caused by a dysfunction or failure in this process
at one level or another. This could be the case in PD where astro-
cytes have been shown to play a crucial role in the initiation and
progression of the disease (Lee et al., 2010; Halliday and Stevens,
2011; Sathe et al., 2012) as the distribution of α-synuclein-positive
astrocytes parallels the distribution of Lewy bodies (Braak et al.,
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2007). Moreover loss of DA neurons in the substantia nigra
pars compacta is knowingly associated with an increase number
of activated astrocytes (Hirsch et al., 2003; Gomide and Chadi,
2005; Mcgeer and Mcgeer, 2008). Astrocytosis in PD was so far
primarily approached from the neurodegeneration angle but its
role might well go beyond these effects. Before embarking into
physiological investigations of the yet-to-be-identified “tripar-
tite” synapses in the basal ganglia in general and the striatum
in particular, we therefore characterized anatomically the PD-
related modifications in astrocytic morphology, the changes in
astrocytic network connections and the consequences on the
spatial relationship between astrocytic processes and asymmetric
synapses in normal and PD-like conditions in experimental and
human PD. Our results unravel a dramatic regulation of striatal
astrocytosis supporting the hypothesis of a key role in (dys) reg-
ulating corticostriatal transmission. Astrocytes and their various




Experiments were performed in accordance with French (87-
848, Ministère de l’Agriculture et de la Forêt) and European
Communities Council Directive (2010/63/EU) for care of labo-
ratory animals and were approved by the Ethical Committee of
Center National de la Recherche Scientifique, Région Aquitaine
(5012099-A).
6-hydroxydopamine (6-OHDA) rats
Adult male Sprague Dawley rats (Charles River Laborato-
ries) weighing 175–200 g were sham operated and 6-OHDA-
lesioned (n = 4/group) with injection (3 µg/µl) in the right
medial forebrain bundle (2.5 µl at anteroposterior = −3.7 mm,
mediolaterial = +1.7 mm and dorsoventral = −8 mm, rela-
tive to bregma) after pretreatment with citalopram (1 mg/kg
i.p.; Lundbeck), an inhibitor of serotonin reuptake, and with
desipramine hydrochloride (20 mg/kg i.p.; Sigma-Aldrich), an
inhibitor of noradrenergic reuptake, as previously described
(Charron et al., 2011; Porras et al., 2012). A >95% loss of
tyrosine hydroxylase (TH)-immunopositive fibers in the striatum
was required for inclusion. Animals were terminated 30 days
post-surgery.
6-OHDA mice
45-day-old laboratory-bred adult male C57BL/6 mice weighting
30 ± 3 g received unilateral stereotaxic intra right medial fore-
brain bundle injection of vehicle (1 µl) or 6-OHDA (3 µg/µl)
(n = 5/group) at the following coordinates according to the mouse
brain atlas: AP −0.7; L −1.2; DV −4.7 as previously described
(Fasano et al., 2010). On day 21, all animals were sacrificed and
severity of DA denervation was assessed by analyzing striatal levels
of TH.
Reserpine mice
45-day-old laboratory-bred adult male C57BL/6 mice weighting
30 ± 3 g were injected with either saline (controls) or a combi-
nation of 2.5 mg/kg reserpine i.p. (Sigma Aldrich) at 24 h and
100 mg/kg of α-methyl-p-tyrosine (Sigma Aldrich) (n = 4/group)
24, 16, 4 and 1 h before sacrifice, as previously described (Berthet
et al., 2012).
Terminal procedure
Animals were deeply anesthetized with chloral hydrate (150
mg/kg i.p., VWR) and transcardially perfused with 2%
paraformaldehyde (PFA) and 0.2% glutaradehyde. Brains
were post-fixed overnight in 2% PFA at 4◦C. Coronal
sections were cut at 50 µm on a Vibratome (Leica, VT
1000S, Wetzlar, Germany) and collected in phosphate buffer
saline (PB saline (PBS) pH 7.4). To enhance the penetration
of immunoreagents, the sections were equilibrated in a
cryoprotectant solution, PBS with 25% saccharose, freeze
thawed in isopentane and stored in PBS with 0.03% sodium azide
at 4◦C.
NON-HUMAN PRIMATE MATERIAL
All experiments were carried out in accordance with the Euro-
pean Communities Council Directive (2010/63/EU) for care of
laboratory animals in an AAALAC-accredited facility and were
approved by the Institute of Lab Animal Science IACUC. Ani-
mals were housed in individual primate cages under controlled
conditions of humidity (50 ± 5%), temperature (24 ± 1◦C)
and light (12 h light/12 h dark cycles, time lights on 8:00 am),
food and water were available ad libitum and animal care super-
vised by veterinarians skilled in the healthcare and maintenance
of non-human primates. Six female macaca mulatta monkeys
(Xierxin, Beijing, PR of China), previously presented in Fernagut
et al. (2010), Santini et al. (2010) and Porras et al. (2012),
were either kept normal (control, n = 3) or intoxicated with
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) hydro-
chloride (MPTP, n = 3). Bilateral parkinsonian syndrome had
stabilized for 6 months without any dopaminergic supplemen-
tation before termination. Animals were deeply anesthetized
with sodium chloral hydrate (150 mg/kg) and perfused tran-
scardially with 4% PFA in phosphate buffer (PB, 0.1 M).
Brains were removed, bisected along the midline, stored in 2%
PFA overnight at 4◦C, and cut into 60 µm frontal sections
with vibratome (Leica, VT1000S, Wetzlar, Germany). Sections
were collected in PBS, cryoprotected in PBS with 25% sac-
charose, freeze-thawed in isopentane and stored in PBS with
0.03% sodium azide until use. The clinical assessments and
the characterization of the extent of nigrostriatal denervation
have been previously published (Fernagut et al., 2010; Santini
et al., 2010; Porras et al., 2012) showing that all the MPTP-
treated animals displayed comparable lesion of the nigrostriatal
pathway.
POST-MORTEM HUMAN SAMPLES
The observations on human tissue were based on the analysis of
formalin fixed and paraffin embedded human specimens from
an archival collection (Comité Protection des Personnes No.
CEBH 2009/03; Ministère Enseignement Supérieur et Recherche:
DC-2008-337) declared and approved by the ethics committee
(“Comité de Protection des Personnes Sud-Ouest et Outre Mer
III”) of Bordeaux University Hospital (Charron et al., 2011).
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Striatum material was available for both neuropathologically-
confirmed cases of PD (n = 3; 2 males, 1 female; 62 ± 7 years old
at death) and controls with no detectable central nervous system
disease (n = 3; 2 males, 1 female; 63 ± 8.5 years old at death)
(Charron et al., 2011). The post-mortem delay was similar for all
cases (<24 h) but the female PD case with 60 h. The striatum
was studied within a coronal 5 mm-thick section demonstrating
connections between the head of the caudate and the putamen
across the internal capsule.
IMMUNOHISTOCHEMICAL PROCEDURES
IMMUNOPEROXYDASE LABELING ON ANIMAL MATERIAL
The number of striatal and globus pallidus (GP) astrocytes were
defined after immunolabeling with the peroxydase technique
(Charron et al., 2011). Sections were incubated overnight at room
temperature (RT) in a combination of two primary antibod-
ies directed against two complementary markers of astrocytes,
i.e., Glial fibrillary acidic protein (GFAP; MAB3402, Millipore
or Z03334, Dako) and S100β (PAB11341, Abnova or Ab7852,
Abcam), a calcium-binding protein synthesized in, and constitu-
tively secreted, by astrocytes (Van Eldik and Zimmer, 1987; Sorci
et al., 2010). This was then incubated in biotinylated secondary
antibody and then in avidin-biotin complex (ABC; Vectastain
Elite ABC kit). Immunoreactivity was revealed with Novared kit
(Vector Laboratories).
IMMUNOPEROXYDASE LABELING ON HUMAN SAMPLES
4 µm-thick paraffin-embedded striatal sections were processed
as previously described (Vital et al., 2009; Charron et al., 2011).
Briefly, sections were dewaxed, pressure-cooked in sodium citrate
buffer (0.1 M, pH 6.0), washed, blocked with a universal blocking
buffer (Biogenex) and incubated with GFAP antibody overnight.
Control sections were incubated with blocked antiserum. After
transfer in 3% H2O2/PBS, the sections were treated with a ready-
to-use goat anti rabbit En Vision-HRP enzyme conjugate (Dako,
Trappes, France) for 30 min. The color was developed using the
highly sensitive diaminobenzidine plus (DAB+) (Dako, Trappes,
France). Sections were counterstained with Mayer’s hemalum
and mounted with an aqueous agent for microscopy (aquatex;
Merck).
IMMUNOFLUORESCENT LABELING
Astrocytes were detected by fluorescent immunohistochem-
istry using anti-GFAP, anti-S100β or anti-Glutamate Transporter
(GLT1; AB1783, Millipore) antibodies (Chaudhry et al., 1995;
Lehre et al., 1995). Sections were incubated with Normal donkey
serum (NDS) containing 0.05% tween 20 for 45 min and then in
primary antibody supplemented with 1% NDS overnight at RT.
After thorough washing, sections were incubated for 90 min at
RT in secondary antibody conjugated to alexa 568 fluorochrome
(1:400 Invitrogen).
IMMUNOFLUORESCENT DOUBLE-LABELING
Those experiments aimed at studying the distribution and the
composition of GJs connecting the astrocytes to form the astro-
cytic network (Giaume et al., 2010). GJs are formed of Cx of
various molecular weights, e.g., Cx30 (728, Invitrogen) or Cx43
(MAB3068, Millipore). Dual labeling of GFAP and any Cx was
achieved as described above except that two primary antibod-
ies derived from different animal species were applied together.
Similarly, two secondary antibodies raised in different species and
labeled with two fluorochromes, alexa 488 against rabbit and alexa
568 against mouse, were applied.
IMMUNOPEROXIDASE LABELING AT ELECTRON MICROSCOPY LEVEL
GLT1 used as astrocyte marker was detected at subcellular level.
Sections were incubated in 4% normal goat serum (NGS) for
45 min, then in GLT1 antibody (1:1000) supplemented with
1% NGS overnight at RT and finally incubated for 90 min at
RT in biotinylated goat anti-guinea pig (1:200, Jackson Immuno
Research). After rinsing, ABC (1:200 in PBS, Vectastain Elite
ABC kit, Vector laboratories, Burlingame, CA) for 90 min at RT.
Peroxidase activity was revealed by the glucose oxidase- DAB-
nickel method (Shu et al., 1988). Negative immunohistological
control demonstrated the absence of signal when omitting the
first antibody. The sections were rinsed, post-fixed in 1% osmium
tetroxide and dehydrated in ascending series of ethanol dilutions
that also included 70% ethanol containing 1% uranyl acetate.
They were then treated with propylene oxide, impregnated in
resin overnight (Durcupan ACM; Fluka, Buchs, Switzerland),
mounted on glass slides and cured at 60◦C for 48 h. Areas
of interest were cut out from the sections and glued to blank
cylinders of resin. Ultrathin sections were collected on pioloform-
coated single slot copper grids.
IMMUNOGOLD LABELING
GLT1 and Cx30 were analyzed at the electron microscopic level
specifically in striatum by the pre-embedding immunogold tech-
nique as previously described (Dumartin et al., 1998, 2000;
Guigoni et al., 2007; Berthet et al., 2009). Sections were incubated
in 4% NDS for 45 min and then in GLT1 (1:1000) or Cx30
(1:500) for 48 h at 4◦C. After washing in PBS, the sections were
incubated for 2 h at RT in biotinylated donkey anti-rabbit (1:200
GE Healthcare UK) or biotinylated goat anti-guinea pig (1:200
Jackson). After rinsing in (PBS, 2% BSAc, 0.2% Gel), sections
were incubated in Nanogold streptavidine (1:100 in PBS BSAc
Gel) for 3 h. The sections were then washed and post- fixed in
1% glutaraldehyde for 10 min. after rinsing in H2O, the signal of
the immunoparticles was increased using a silver enhancement kit
(HQ Silver, Nanoprobes, USA).
IMAGE ANALYSIS
Fluorescent images were captured on a confocal Leica microscope
DM 2500 TCS SPE. Digital images were acquired separately for
each wavelength [488 nm (green) and 568 nm (red)] and then
merged. Any adjustments to brightness and contrast were made
uniformly to all parts of the image. Cell counting and measure-
ment of astrocyte diameter were performed using a computerized
image analysis system (Mercator V6.50, Explora Nova) linked to
a Leica microscope type DM 6000B (x20 objective). Quantitative
analysis was carried out on the whole striatum or GP areas on at
least three sections per animal and results were expressed as an
average density of astrocyte per µm2. To minimize the inherent
variability in the immunochemical procedures, comparisons were
Frontiers in Aging Neuroscience www.frontiersin.org September 2014 | Volume 6 | Article 258 | 3
Charron et al. Astrocytosis in parkinsonism
made in tissue sections that were processed simultaneously. Only
those astrocytes that were on the surface of the sections, where
antibody penetration was guaranteed, were counted. The length
of astrocytic processes was defined as the distance between the
soma and the detectable end of an extended process identified by
GFAP staining. Astrocyte diameter was determined by measuring
the longest axis of the cell body through the nucleus.
DEFINITION OF ASTROCYTE SURFACE AREA AND CONNEXIN
REPARTITION
Tissue sections were examined with a confocal Leica microscope
DM 2500 TCS SPE. Z-axis image stacks were acquired (37 images,
0.3 µm Z-step size) using the optimal pixel size relative to the
objective used (HCX PL Apo CS 63X). Imaris software (Bitplane
AG, Zurich Switzerland) was used to create 3-D reconstruction
and morphometric measurements. The surface function was used
to reconstruct GFAP-labeled cell bodies and processes of astro-
cytes and evaluate the covered area within a given volume. The
spot module was used to define the pinpointed location of Cx with
red point objects and numerate immunopositive spots.
DEFINITION OF ASTROCYTE PROCESS REPARTITION AT SUBCELLULAR
LEVEL
The analysis of the number of asymmetrical synapses was per-
formed on digital images obtained with a computer-linked CCD
camera (Gatan) mounted on Hitachi H-7650 electron micro-
scope at a final magnification of 15000 using the Metamorph
software (version 4.6r5, Universal Imaging, Paris, France). GLT1
positive astrocytic processes surrounding asymmetric synapses
were considered as GLT1 positive complex. To eliminate arti-
factual differences in the numbers of labeled profiles, an issue
classically related to the limited penetration of immunoreagents,
electron microscopic images were examined only from thin sec-
tions collected from the most superficial vibratome sections.
The measures were performed on four animals per group on
a minimum of 30 randomly selected dendritic fields. A den-
dritic field is defined as an area that does not contain a cell
body. Indeed, given the difference in size between cell body and
dendrites, the presence of a cell body in the randomly selected
counting area would imbalance the counting procedure. 1900
asymmetric synapses were observed in 130 dendritic fields. The
results are expressed as the proportion of GLT1 positive or
GLT1 negative synaptic complex present in the striatum of each
individual.
RESULTS
ASTROCYTE MORPHOLOGY IN CONTROL ANIMALS AND HUMAN
Immunodetection of astrocytes requires using at least two co-
localizing markers, namely GFAP and S-100β, as they label
distinct components of the astrocytes (Boyes et al., 1986; Raponi
et al., 2007). S-100β locates mainly within astrocytic cytoplasm
while GFAP reveals the cytoskeletal structure and delineates the
glial processes, especially of activated astroglial cells, with the limit
of labeling only the structure of primary branches, i.e., up to 15%
of the total astrocyte volume (Bushong et al., 2002). In addition,
S-100β expression in GFAP-positive cells defines a mature astro-
cytic stage (Raponi et al., 2007). Astrocyte morphology is strik-
ingly similar across species (mouse, rat, macaque and human)
although clearly different between the striatum (Figure 1A) and
the GP (GP in rodents, GP pars externalis—GPe—in primates;
Figure 1B). While striatal GFAP-S-100β positive cells are proto-
plasmic astrocytes with round somata and numerous short, thin
and ramified processes (Figure 1A), GP-positive cells are certainly
protoplasmic astrocytes as well but the majority present a roughly
FIGURE 1 | Astrocytic reaction to dopamine depletion in striatum
and GP of animal models of PD and parkinsonian patients.
Dopamine depletion increase GFAP-S100β immunolabeing in striatum
(A) and GP (B) of reserpine mouse, 6-OHDA rat, MPTP non-human
primate models of PD and PD patients (scale bar
= 30 µm).
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fusiform shape. In both structures, and whatever the species,
astrocytes are grouped in close vicinity of capillaries.
ASTROCYTE MORPHOLOGY IN EXPERIMENTAL PARKINSONISM
AND PD
Experimental parkinsonism and PD induced an increase in
immunostaining intensity of GFAP-S-100β in both the striatum
(Figure 1A) and GP (Figure 1B), whatever the considered species
(mouse, rat, macaque and human) or modeling methodology
across species. The main cellular processes are thicker and the
number of primary processes leaving the soma is increased as well.
Parkinsonism-associated astrocytes display a larger soma (up to
20% larger) in both the 6-OHDA rat (p < 0.001, Figure 2A) and
the MPTP-treated macaque (p < 0.001, Figure 2A). Such hyper-
trophy of GFAP-containing cellular processes is characteristic of
reactive astrocytes.
Longer processes once activated (Figure 2A) are however
observed in primates rather than in the rat (Figure 2A), as
reported as well in humans. When visualized by antibodies against
intermediate filament protein GFAP, these thicker processes in
macaque appear longer (Figure 2A) than in the rat (Figure 2A)
because they can be followed over greater distances.
Two astroglial cell populations could be distinguished by their
morphology: a first group featuring astrocytes with high staining
intensity, a few large and long processes and a second group with
low staining and thin processes (Figure 2A). Activated astrocytes
in MPTP-treated macaque or in human PD show very long
glial processes with some enlargements, more or less regularly
arranged along the length (Figure 2A). In the MPTP-treated
macaque, the longest processes vary in length from < 90 to
> 300 µm with an average length of 190 mm ± 8 µm based on
GFAP immunolabeling (n = 150 processes, measured from n = 3).
Previous report in human cortex had noted such long processes
associated with an increased complexity (branching) (Oberheim
et al., 2009), an observation similar to ours in MPTP-treated
macaque and in human PD that is not seen in the 6-OHDA-
lesioned rat model.
INCREASE IN NUMBER OF ASTROCYTES IN EXPERIMENTAL
PARKINSONISM
The above results show that the intensity of labeling increases in
experimental parkinsonism and in human PD, likely reflecting
the activation of astrocytes with larger somas and longer/thicker
processes. We then counted the number of astrocytes in the
experimental parkinsonism (reserpine-treated mouse, 6-OHDA-
lesioned mouse and rat, MPTP-treated macaque) and in human
PD both in the striatum and the GP (GPe in primates). Whatever
the method for generating experimental parkinsonism, both acute
DA depletion (reserpine) and chronic nigrostriatal degeneration
(6-OHDA, MPTP) induce a significant increase in the number
of striatal astrocytes (p < 0.05, Figure 2B). In human PD, there
is only a trend for an increase in the number of astrocytes
in the caudate nucleus (Figure 2B), a result likely to be the
consequence of the tissue quality, the post-mortem time and
more importantly the chronic exposure of patients to a number
of drugs with unknown impact upon astrocytosis. Experimental
data suggest that L-dopa, the reference treatment of PD likely
used by patients, does not normalize the number of astrocytes
(data not shown) but PD patients receive polytherapies for their
parkinsonism and other age-related conditions. Pattern is how-
ever less obvious in the GP with a significant increase in the
reserpine-treated mouse and the 6-OHDA-lesioned rat but not
in the 6-OHDA-lesioned mouse, the MPTP-treated macaque or
human PD. Of note however is the consistently higher number
of astrocytes in the GP than in the striatum in animals and in
humans (Figure 2B).
INCREASE IN ASTROCYTE AREA IN EXPERIMENTAL PARKINSONISM
To determine whether hypertrophy of cellular processes affects
the area of tissue reached by reactive astrocytes, we compared
the area accessed by reactive astrocytes vs. nonreactive astro-
cytes (GFAP immunolabeling) in the striatum and the GP of
6-OHDA-lesioned rats and MPTP-treated macaques. The tri-
dimensional reconstruction is illustrated for these two mod-
els as well as for human PD (Figure 2C left), unraveling that
astrocytes occupy a larger striatal volume in both experimental
parkinsonism and human PD. There is a significant increase
in the astrocytic area in the striatum of 6-OHDA-lesioned rats
and MPTP-treated macaques (p < 0.001, Figure 2C) and in
the GP of the 6-OHDA-lesioned rats (p > 0.001, Figure 2C).
Semi-quantitative measurement in human PD (limited by the
human material quality and the unknown duration and dose
exposure to DA replacement therapy in their lifetime) shows a
17% increase as well in astrocyte area. The very large increase
in striatal volume occupied by astrocytes in parkinsonism is
likely primarily due to the lengthening and the thickening of
astrocyte processes since the enlargement of soma size remains
modest (though significant, Figure 2A), enabling the astrocytes
to modulate excitatory striatal transmission in parkinsonism.
Such result contradicts previous observations collected in the
denervated hippocampal region and the electrically-injured cere-
bral cortex (Wilhelmsson et al., 2006) suggesting that despite
the increased thickness of astrocytic cellular processes in those
two areas, astrocytes did not occupy a greater volume of tissue
and did not alter the action radius of reactive astrocytes in
the hippocampus. Morphological and functional responses of
astrocytes likely depend on the type of insult and on the cerebral
region as the astrocytes in DA-depleted striatum occupies a larger
area.
CONNEXIN EXPRESSION IS MODULATED IN EXPERIMENTAL
PARKINSONISM
Considering that experimental parkinsonism induces a large
increase in astrocytic volume and that astrocytes are organized
into functional networks through interconnection via intercel-
lular GJs composed of Cx (Giaume and Mccarthy, 1996; Nagy
et al., 1999; Dermietzel et al., 2000), we sought to determine
if expression pattern and density of Cx30 and Cx43 connexins
were affected by DA depletion. Distribution of Cx43 (Figure 3A)
and Cx30 (Figure 3B) is heterogeneous with higher expression
of both Cx in the GP than in the striatum. Cx30 (Figure 3B)
and Cx43 (Figure 3A) stainings in the striatal and GP neuropil
of 6-OHDA-lesioned rats were differentially affected. Immunos-
taining greatly strengthened around vessels for both Cx43 and
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FIGURE 2 | Morphological and quantitative analysis of astrocytic
reaction to dopamine depletion in striatum and GP of animal models of
PD and parkinsonian patients. (A) GFAP-S100β immunostaining enables
demonstrating significant increase in astrocyte soma diameter in the rat and
monkey models of PD (n = 4 sham and 4 6-OHDA rats; n = 3 control and 3
MPTP monkeys; mean ± SEM) (scale bar = 30 µm but in inset, 10 µm).
Primates show two level of immunoreactivity indicated by a black arrowhead
for intense labeling and a white arrowhead for moderate staining. (B)
Quantitative analysis of astrocyte number in striatum and GP in controls and
in animal models of PD (n = 4 reserpine mouse, n = 5 6-OHDA mouse, n = 4
6-OHDA rat, n = 3 MPTP non-human primate) as well as in parkinsonian
patients (n = 3) showing increase in astrocyte number. * denotes a significant
difference (Student t-test; p < 0.05).
(Continued )
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FIGURE 2 | Continued
(C) Area analysis of astrocytic processes after GFAP immunostaining and
3D reconstruction. Left: representative examples of GFAP immunostaining
in the striatum of 6-OHDA rat and MPTP monkey models of PD as well as in
PD patients (Scale bar = 30 µm). Right: Astrocytic area significantly
increases in the striatum of 6-OHDA rat (n = 4) and MPTP monkey (n = 3)
models of PD. * denotes a significant difference (Student t-test ; p < 0.05).
Cx30 (Figures 3A,B), suggesting an increased metabolic cou-
pling. Electron microscopy observations confirmed the local-
ization of Cx30 along the inner gap junctional membranes of
astrocytic processes (Figure 3C). Cx30 expression is particu-
larly abundant between neighboring astrocytes (Figure 3C-2),
between astrocytes processes (Figure 3C-4-5), in astrocytic pro-
cesses sheathing chemical synapses (Figure 3C-3) as well as on
the astrocytic end feet surrounding blood vessels (Figure 3C-5).
Quantitative assessment of connexin expression was achieved
using immunohistochemical labeling followed by 3-D reconstruc-
tion and automated quantification of the number of Cx positive
puncta, a measurement performed strictly in neuropil area devoid
of vessels (Figure 3D). The 6-OHDA-lesioned rat displayed an
increased density of Cx30 in the striatum (Figure 3E) but not
of Cx43 and none of the two Cx in the GP (Figure 3E). The
MPTP-treated monkey however showed a decrease in Cx30 levels
in the striatum but not in the GP (Figure 3F). Altogether, these
data suggest that, while astrocytosis is massive in experimental
parkinsonism, it is not associated with an increased coupling
between astrocytes but might be associated to an increased
metabolic coupling. However, the functional impact of alterations
in connexin expression on metabolite trafficking through astro-
cytic networks has never been directly assessed in any neurode-
generative diseases.
INCREASED ASTROCYTIC “CONTROL” OF STRIATAL ASYMMETRIC
SYNAPSES IN PARKINSONISM
Tripartite synapses, i.e., the structure consisting of pre- and
post-synaptic elements of the synapse and an associated astro-
cyte process (Perea et al., 2009; Parpura et al., 2012; Santello
et al., 2012), are a marker of increased control of astrocytes
upon synaptic transmission. The loss of nigrostriatal DA neurons
results in medium spiny neuron spine retraction, and the loss
of glutamatergic asymmetric synapses in rodent (Ingham et al.,
1989; Day et al., 2006; Schuster et al., 2009; Zhang et al., 2013;
Suárez et al., 2014) and primate (Scholz et al., 2008; Villalba and
Smith, 2011) models of PD. Given the dramatic changes affecting
astrocytic morphology in striatum of experimental parkinsonism
and human PD, we investigated at electron microscopy level the
evolution of the relationship between the astrocytic processes
and the asymmetric synapses representing the corticostriatal and
thalamostriatal glutamatergic input, using immunohistochemical
methods (immunogold or peroxidase) with antibodies against
the glutamate transporter GLT1 as astrocytic plasma membrane
marker. GLT1 is predominantly expressed in astroglia, found
both in astrocytic cell bodies and in the smallest ramifications
of the astrocytes close to synapses and around blood vessels
(Chaudhry et al., 1995; Lehre et al., 1995) and is heavily expressed
in striatum (Lehre et al., 1995; Figure 4A). We considered as
GLT1-positive asymmetric synapses only those that were GLT1
immunoperoxidase-labeled on the edge of axon-dendrite inter-
faces (Figure 4B). Quantitative analysis unraveled a significant
reduction (9%, p < 0.05) in asymmetric synapses in 6-OHDA
rats compared with controls (Figure 4C) in agreement with
literature (Ingham et al., 1989; Day et al., 2006; Scholz et al.,
2008; Schuster et al., 2009; Villalba and Smith, 2011; Zhang
et al., 2013). Asymmetric synapses surrounded by GLT1-positive
astrocytic processes were however increased in 6-OHDA rats (p
< 0.05; Figure 4D) while those not surrounded by astrocytic
processes dramatically decreased (p < 0.05; Figure 4D). These
data suggest that, while the nigrostriatal lesion induces a loss in
striatal asymmetric synapses, the astrocytic control over striatal
glutamatergic transmission increases in parkinsonism.
DISCUSSION
The study of the PD-related modifications in astrocytic morphol-
ogy unraveled that DA depletion or denervation is accompanied
in the striatum by a dramatic increase in astrocyte number
(+20%), in the astrocyte volume (+60%) and in the number of
glutamatergic synapses contacted by GLT1+ astrocytic contacts
(+15%). These unequivocal data support our hypothesis of a
dramatic regulation of striatal astrocytosis in position for (dys)
regulating excitatory striatal input, i.e., arising from cortex and
thalamus.
The present work, undertaken in four animal models of PD
as well as in human PD brains, highlights that in response to
DA denervation or PD, astrocytes undergo characteristic pheno-
typic changes known as reactive astrogliosis, a non-specific but
highly characteristic response that involves various morphological
and molecular changes. Whatever the animal model of PD or
human parkinsonism, we observe in both the striatum and GP,
an enlargement of astrocyte cell body, a remodeling of processes
and an increase in astrocyte number that are indications of
reactive gliosis in agreement with previous studies (Muramatsu
et al., 2003; Dervan et al., 2004; Gomide and Chadi, 2005; Même
et al., 2006; Henning et al., 2008). The grade of astrogliosis
appears however to be directly related to the method by which
the dopaminergic lesion was induced. Reactive astrogliosis is
actually not a simple all-or-nothing phenomenon but, rather, a
finely gradated continuum of molecular, cellular and functional
changes ranging from subtle alterations in gene expression to
scar formation. Dysfunction of either astrocytes or the process
of reactive astrogliosis is emerging as an important source of
potential mechanisms that might contribute to, or play primary
roles in, a host of CNS disorders via loss of normal or gain of
abnormal astrocyte activities.
Our observations show in striatum and GP morphological dif-
ferences between primate and rodent astrocytes with an increased
complexity and size of primate protoplasmic astrocytes, an inter-
order feature previously noted for cortical astrocytes (Oberheim
et al., 2009).
Individual astrocytes play a major role in synaptic physiol-
ogy by controling a large number of synapses, in part through
gliotransmission, or glutamate and K+ uptake (Nedergaard and
Verkhratsky, 2012). However, another key property of astrocytes
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FIGURE 3 | Qualitative and quantitative assessment of connexin 30 and
43 expression in rat and monkey models of PD. Connexin 43 (A) and 30
(B) distribution at cellular level in the striatum (top row) and GP (bottom row)
of sham and 6-OHDA rat model of PD. Images correspond to the Z projection
of six deconvolved 1 µm optical sections through section, red staining for Cx
and blue for nucleus. Insets point out representative Cx immunolabeling
around vessels (left) or in neuropil at distance from vessels (right) (scale
bar = 10 µm). (C) 1-Representative electron micrographs showing Cx30
localization (scale bar = 1 µm); 2-symmetrically labeled gap junction between
two astrocytic soma (white arrow; As = astrocyte) (scale bar = 0.5 µm) ; 3-
symmetrically labeled gap junction between two astrocytic processes (black
arrow; AsP = astrocytic process) (scale bar = 0.5 µm); 4-symmetrically
labeled gap junction between two astrocytic processes close to asymmetrical
synapse (scale bar = 0.5 µm); 5-asymmetrical labeled gap junction between
two astrocytic processes (scale bar = 0.5 µm). (D) Illustration of
quantification methodology of connexin based on double immunolabeling.
GFAP immunostaining appears in green while Cx 30 immunostaining appears
in red (scale bar = 2 µm). (E) Connexin Cx30 and Cx43 quantification in the
6-OHDA rat and (F) in MPTP monkey models of PD expressed in percentage
of levels measured in control animals.
is their extensive network communication via intercellular GJ
channels, formed by Cx. These Cx are poorly selective channels
allowing direct cytoplasmic exchange of a variety of small
molecules like ions, second messengers, neurotransmitters or
energy metabolites (Giaume and Mccarthy, 1996; Dermietzel
et al., 2000; Giaume and Theis, 2010). The two main Cx expressed
in astrocytes are connexin 43, present from embryonic stages
to adulthood, and connexin 30, expressed after postnatal day
10 (Nagy et al., 1999). GJ channels mediate the formation of
large cellular ensembles reaching millimeter size in different brain
regions, encompassing hundred to thousands of astrocytes (Ball
et al., 2007; Giaume and Theis, 2010). Nevertheless, these connec-
tions can be selective and preferential since adjacent astrocytes are
not always functionally connected (Houades et al., 2006) which
may result from heterogeneous expression of Cx in astrocytes,
or to short-term regulation of astroglial GJ permeability. Clas-
sically, a reactive gliosis is associated with modifications in the
expression and function of these astrocytic Cx (Giaume et al.,
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FIGURE 4 | Astrocytes further contacts asymmetric striatal synapses
after dopamine depletion. (A) Electron micrograph of GLT1
immunolabeled striatal astrocytes colored in green (pseudocolor image
NHI Image J) (scale bar = 2 µm). (B) GLT1-positive astrocytic processes
surrounding (asterisk) or not surrounding asymmetric striatal synapses
(arrowhead) (scale bar = 0.5 µm). (C) A significant decrease in the
number of asymmetric synapses is observed in 6-OHDA rat striatum
compared with control (n = 4 animals per group; Student t-test; p <
0.05). (D) Such decrease however decomposes in a significant increase
in GLT1+ asymmetric synapses and a dramatic decrease in the number
of GLT1− asymmetric synapses in the 6-OHDA rat compared to controls
(n = 4 animals per group; one-way ANOVA followed by Bonferroni; p <
0.05).
2010, 2013). Our study shows a differential modulation in Cx
expression in the rat and monkey model of PD preventing any
final conclusion to be drawn about quantitative changes within
a given structure. Interestingly however, both species showed a
higher expression of both Cx in the GP than in the striatum (Nagy
et al., 1999), a feature that was maintained in the parkinsonian
condition. The consolidation of astroglial networks in the GP
may favor specific neuroglial interactions. Indeed, this might
contribute to local and precise processing of neuronal signals,
favoring circuit independence by restricting information transfer
to distal neurons, belonging to the GP. This region-dependent
organization of astroglial networks may also directly influence
how distant neurons with high-energy needs, within a specific
network, are supplied with metabolites taken up by perivascular
astrocytes.
We found an increased expression of both Cx30 and Cx43
in perivascular astrocytic endfeet and delineation of blood
vessel walls in rat and monkey models of PD. The func-
tional connectivity of perivascular astrocytic networks has
been hypothesized to contribute to neurometabolic coupling
since astroglial Cx mediate an activity-dependent glucose dis-
tribution through intercellular astroglial networks (Rouach
et al., 2008). Astrocytes actually define the local availability
of energy substrates by regulating blood flow. Subsequently,
in order to efficiently reach distal neurons, these substrates
can be taken up, and distributed through networks of astro-
cytes connected by GJ, a process modulated by neuronal
activity.
We highlighted that Cx show differential changes in the two
animal models of PD, thus further studies are needed to sort
out this question. While the reactive astrogliosis occurs following
acute (reserpine) or chronic (6-OHDA, MPTP, human PD) DA
depletion, Cx expression regulation, and hence, physiological
function, might well takes time to establish and the regulatory
mechanisms may be different, thereby explaining the differences
between the 6-OHDA rat (3 weeks of depletion) vs. the MPTP
monkey (few months of depletion).
A striking observation of the study is that asymmetric exci-
tatory cortico- or thalamo-striatal synapses decrease in 6-OHDA
rats compared with controls (Figure 4C), a result in agreement
with literature in the 6-OHDA rat (Ingham et al., 1989; Day
et al., 2006; Scholz et al., 2008; Schuster et al., 2009; Donnelly
et al., 2013; Suárez et al., 2014) and in the MPTP-treated macaque
monkey (Villalba and Smith, 2011). Further investigations of
vGLUT1 and vGLUT2-labeling of asymmetric synapses would
help defining if the cortico-striatal or thalamo-striatal pathways,
respectively (Raju et al., 2008), are affected comparably or dif-
ferentially by an increased apposition of GLT1+ astrocyte feets.
In parkinsonism, we have clearly identified changes in astrocytic
morphology which are accompanied by processes reorganization
at the level of asymmetric synapses.
A major role of astrocytes is the uptake of neurotransmitters
allowed by the presence of astrocytic transporters which remove
most of the glutamate that spills over the synaptic cleft (Kullmann
and Asztely, 1998; Danbolt, 2001; Goubard et al., 2011). In
rodents, GLT1, highly expressed in astrocytes, is responsible for
the largest proportion of total glutamate uptake in the forebrain
(Rothstein et al., 1996; Tanaka et al., 1997). Astrocytes express
also, at a lower level, glutamate-aspartate transporter (GLAST).
The astrocyte to neuron lactate shuttle (ANLS) hypothesis states
that enhanced neuronal activity at glutamatergic synapses stim-
ulates the uptake of glutamate, which is co-transported with
Na+ in astrocytes via GLT1 or GLAST. Restoration of the Na+
gradient by the Na/K ATPase pump consumes ATP, whose levels
are recovered by an enhanced uptake and glycolysis of glucose
in astrocytes. Glycolysis in astrocytes leads to rapid production
of lactate, which is then transported to neurons, thereby fuel-
ing their energy needs (Pellerin and Magistretti, 1994). A very
tight cooperation between astrocytes and neurons for glucose
oxidation in conditions of enhanced neuronal activity is now
well documented, allowing to a enhanced neuronal activity to
be translated into an increased uptake of glucose in the active
regions.
We highlighted that, while the nigrostriatal lesion induces
a loss in striatal asymmetric synapses, the astrocytic control
over striatal glutamatergic transmission increases in PD. Such a
phenomenon can affect the extracellular space and likely regu-
lates metabolic exchanges at the tripartite synapse, placing such
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synaptic organization in key position for playing a role in expres-
sion of cortico-striatal transmission-related symptoms (Goubard
et al., 2011). In a seminal study, Goubard et al. showed that
glutamate and GABA uptake by astrocytes plays a key role in the
corticostriatal information processing, thereby heavily participat-
ing in the filtering of corticostriatal information (Goubard et al.,
2011). One can thus hypothesize that such filtering is impaired in
PD-like DA-depleted situations and that astrocytosis plays a yet
unacknowledged role in PD pathophysiology.
Our results unravel a dramatic regulation of striatal
astrocytosis supporting the hypothesis of a key role in (dys)
regulating excitatory cortico-/thalamo-striatal transmission.
Such fine-tuning of excitatory transmission must now be
investigated electrophysiologically. Astrocytes and their various
properties could thus represent an interesting therapeutic target
for symptomatic management in PD.
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